Skip to main
KURA

Kura Oncology (KURA) Stock Forecast & Price Target

Kura Oncology (KURA) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 63%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kura Oncology Inc. exhibits a positive outlook due to its strong pipeline and significant early commercial momentum, particularly with the initial sales of KOMZIFTI, projected to remain robust into 2026. The company maintains a substantial cash balance of approximately $667 million at the end of 2025, offering the necessary resources and flexibility to advance its clinical and commercial strategies effectively. Moreover, the partnership with Kyowa Kirin is seen as a highly synergistic collaboration, leveraging shared expertise in oncology, which is expected to enhance Kura's market presence in treating hematologic malignancies.

Bears say

Kura Oncology faces significant risks that may hinder its stock performance, including the potential ineffectiveness or safety concerns surrounding key therapies, ziftomenib and tipifarnib, which could lead to halted development. The company's ability to secure funding for continued drug progression is uncertain, and the overall success of its clinical trials remains a major obstacle to achieving projected sales estimates. Furthermore, competitive challenges from existing and emerging therapies, along with the regulatory landscape, add layers of risk that contribute to a negative financial outlook for Kura Oncology.

Kura Oncology (KURA) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 63% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kura Oncology and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kura Oncology (KURA) Forecast

Analysts have given Kura Oncology (KURA) a Buy based on their latest research and market trends.

According to 8 analysts, Kura Oncology (KURA) has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kura Oncology (KURA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.